EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sutro Biopharma's EBITDA for the
three
months ended in Mar. 2026 was €-23.13 Mil. Sutro Biopharma's Revenue for the
three
months ended in Mar. 2026 was €12.56 Mil. Therefore, Sutro Biopharma's EBITDA margin for the quarter that ended in Mar. 2026 was -184.15%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sutro Biopharma EBITDA Margin % Related Terms
Sutro Biopharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S090 vs CCCC, OCGN, FULC: EBITDA Margin % Comparison
For the Biotechnology subindustry, Sutro Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (FRA:S090) has a EBITDA Margin % of -184.15% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sutro Biopharma and its competitors. According to the industry distribution chart, Sutro Biopharma ranks #507 out of 944 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Sutro Biopharma's EBITDA Margin % too high?
Sutro Biopharma's current EBITDA Margin % is -184.15%. Based on the distribution chart, Sutro Biopharma ranks #507 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sutro Biopharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's EBITDA Margin % compare to CCCC and OCGN?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #507 out of 944 companies for EBITDA Margin %. This places Sutro Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current EBITDA Margin % is -184.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (FRA:S090) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.36, compared to a current price of €24.80 — trading 139.4% above its estimated fair value. The current EBITDA Margin % is -184.15%. Sutro Biopharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current EBITDA Margin % is -184.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (FRA:S090) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of €24.80 is trading 139.4% above its estimated GF Value™ of €10.36.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for FRA:S090:
EBITDA Margin %: -184.15%
GF Value™: €10.36 vs. price of €24.80 (139.4% above fair value)
No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
41GF Score
Get the complete analysis for FRA:S090
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S090 has been successfully added to your 
